趙靖靖主治醫(yī)師
中山大學(xué)附屬腫瘤醫(yī)院生物治療中心
1、個人簡介 中山大學(xué)腫瘤防治中心生物治療中心主治醫(yī)師。2013年于中山大學(xué)腫瘤防治中心獲醫(yī)學(xué)博士學(xué)位。主要進(jìn)行腫瘤免疫微環(huán)境、腫瘤免疫治療、腫瘤抑癌基因的篩選及對腫瘤細(xì)胞物學(xué)功能研究。2013年8月博士研究生畢業(yè)后進(jìn)入中山大學(xué)腫瘤防治中心生物治療中心從事腫瘤生物治療臨床研究工作，目前研究方向為腫瘤免疫學(xué)及腫瘤免疫治療。現(xiàn)主持國家自然科學(xué)基金1項、參加多項國家級、省市級基金項目，以第一作者及參與作者發(fā)表SCI論文20余篇。 2、教育經(jīng)歷 2008/09-2013/06，中山大學(xué)腫瘤防治中心，腫瘤學(xué)，博士研究生(碩博連讀)，導(dǎo)師：夏建川教授 2003/09-2008/06，濱州醫(yī)學(xué)院，臨床醫(yī)學(xué)系，本科 3、研究工作經(jīng)歷 2015/01-至今，中山大學(xué)腫瘤防治中心，生物治療中心，主治醫(yī)師 2013/08-2014/12，中山大學(xué)腫瘤防治中心，生物治療中心，住院醫(yī)師 4、主持或參加科研項目 1、國家自然科學(xué)基金青年基金，81402560，細(xì)胞因子IL-37通過腫瘤浸潤免疫細(xì)胞抗肝癌作用的機(jī)制研究，在研，主持。 2、 國家自然科學(xué)基金面上項目，31270964，IL-17細(xì)胞因子及Th17抗原特異性淋巴細(xì)胞抗食管癌作用及機(jī)制研究，在研，參加。 3、 國家自然科學(xué)基金面上項目，81472387，靶向腎癌干細(xì)胞的特異性免疫治療研究，在研，參加。 5、主要論著(近3年) 1. Zhao JJ#, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC*, Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells, Sci Rep, June 5,4:5177,2014 2. Zhao JJ#, Pan K, Wang QJ, Xu ZD, Weng DS, Li JJ, Li YQ, Xia JC*, Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells, Chin J Cancer, 32(10), 553-560, 2013 3. Zhao JJ#, Pan K#, Wang W, Chen JG, Wu YH, Lv L, Li JJ, Chen YB, Wang DD, Pan QZ, Li XD, Xia JC*, The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection, PLoS One, 7(3), e33655, 2012 4. Zhao JJ#, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC*, Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma, PLoS One, 6(10), e26608, 2011 5. Mai C#, Zhao JJ#, Tang XF#, Wang W, Pan K, Pan QZ, Zhang XF, Jiang SS, Zhao BW, Li YF, Xia JC*, Zhou ZW*, Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer, Med Oncol, 31(7):53,2014 6. Huang CY#, Zhao JJ#, Lv L#, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW*, Xia JC*, Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer, PLoS One, 8(7), e69155, 2013 7. Yang XB#, Zhao JJ#, Huang CY#, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, Chen HW, Yao JY, Zhi M*, Xia JC*, Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients, PLoS One, 8(10), e78158, 2013 、 8. Huang CY#, Chen YM#, Zhao JJ#, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW*, Xia JC*, Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis, PLoS One, 8(1), e54671, 2013 9. Pan K#, Guan XX#, Li YQ#, Zhao JJ, Li JJ, Qiu HJ2, Weng DS, Wang QJ, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX*, Xia JC*, Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer, Clin Cancer Res, 20(11),3003-11,2014 10. Pan QZ#, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, Li YQ, He J, Liu Q, Chen CL, Zhang HX, Xia JC, Annexin a3 as a potential target for immunotherapy of liver cancer stem-like cells, Stem Cells,33(2):354-66,2015 11. Chao J#, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, Zhang JH, Xia JC, Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma, Med Oncol, 31(8):102,2014 12. Jiang SS#, Weng DS#, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, Pan QZ, Xia JC*, Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma, J Transl Med, 12(1):273,2014 13. Pan QZ#, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX, Xia JC*, Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma, Mol Carcinog, 2013 Dec 23, 2013 14. Pan K#, Lv L, Zheng HX, Zhao JJ, Pan QZ, Li JJ, Weng DS, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC*, OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity, Immunol Cell Biol, 92(3):263-74, 2013 15. Pan QZ#, Pan K#, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC, Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma, Cancer Immunol Immunother, 62(11),1675-1685, 2013 16. Lu L#, Pan K#, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC*, IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival, J Immunother, 36(8), 451-458, 2013 17. Pan K#, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC*, Zeng YX, The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients, Ann Surg Oncol, 20(13), 4305-4311, 2013 18. Wang DD#, Chen YB#, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC*, Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer, PLoS One, 7(7), e40364, 2012 19. Li JJ#, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC*, Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma, Chin J Cancer, 32(3), 141-148, 2013 20. Chen Y#, Pan K, Li S, Xia J*, Wang W, Chen J, Zhao J, Lu L, Wang D, Pan Q, Wang Q, Li Y, He J, Li Q*, Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer, J Surg Oncol, 106(3), 286-293, 2012 21. Pan K#, Liang XT#, Zhang HK#, Zhao JJ, Wang DD, Li JJ, Lian Q, Chang AE, Li Q, Xia JC*, Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma, Mol Med, 18, 507-518, 2012
?
